Background: Alcohol and nicotine codependence can be considered as a more severe subtype of alcohol dependence. A portion of its risk may be attributable to genetic factors.
A LCOHOL AND NICOTINE are the most commonly misused substances in the United States. Nearly 20 million Americans are alcohol abusing or dependent, and almost 50 million Americans smoke cigarettes (Substance Abuse and Mental Health Services Administration (SAM-HSA, 2010) . Alcohol dependence and nicotine dependence frequently co-occur in the same individuals. Furthermore, nicotine-dependent individuals are 4 times more likely than the general population to be alcohol dependent and people who drink are 3 times more likely than the general population to smoke (Grant et al., 2004) . Identical twins are twice as likely as fraternal twins to become alcohol and nicotine dependent if the other twin is dependent (Carmelli et al., 1993; Swan et al., 1997) . Alcohol and nicotine may enhance motivation to use either drug by activating common brain targets that are responsible for their reinforcing effects. They may also exert synergistic effects on behaviors which may contribute to their concurrent use.
Alcohol and nicotine codependence may represent a more severe subtype of alcohol dependence. A large number of risk loci have been associated with both alcohol dependence and nicotine dependence by candidate gene approach, including many genes that are involved in the dopaminergic, serotoninergic, GABAergic, glutamatergic, cholinergic, opioid, and endocannabinoid systems. However, none of these genes have been confirmed by recent genome-wide association studies (GWASs) of alcohol dependence Edenberg et al., 2010; Heath et al., 2011; Johnson et al., 2011; Treutlein et al., 2009) . Only 2 of them (CHRNA6-CHRNB3 [Thorgeirsson et al., 2010] and CHRNA5-CHRNA3-CHRNB4 [Liu et al., 2010] ) were confirmed by meta-analysis GWASs of nicotine dependence. GWASs of alcohol dependence or alcohol consumption reported multiple other potential risk loci Edenberg et al., 2010; Heath et al., 2011; Schumann et al., 2011; Treutlein et al., 2009) , so did most GWASs of nicotine dependence. To date, there has been only 1 GWAS (Lind et al., 2010) directly studying the phenotype of alcohol and nicotine codependence. That study identified 3 risk genes including ARHGAP10, MARK1, and DDX6. However, those findings have not been replicated independently yet.
In the present study, we searched for significant risk genomic regions for alcohol and nicotine codependence using a GWAS. A European American cohort was used as the discovery one, and a European Australian cohort and an African American cohort were used as the replication ones. Additionally, we used 3 independent samples of European descent to detect expression quantitative trait locus (eQTL) signals in this risk genomic region, to see whether the risk variants were functional. Finally, as contrast, we tested gene -disease associations in 18 additional independent cohorts with 10 other nonalcoholism neuropsychiatric disorders, to see whether the risk regions were specific for alcohol and nicotine codependence or not.
MATERIALS AND METHODS

Subjects
A total of 8,847 subjects underwent gene-disease association analysis, including (i) a discovery cohort of 818 European American cases with alcohol and nicotine codependence (476 males and 342 females; 38.3 ± 10.2 years) and 1,396 European American controls (422 males and 974 females; 39.4 ± 10.4 years), (ii) a replication cohort of 5,704 European Australian family subjects (1,856 families; 2,620 males and 3,084 females; 46.0 ± 10.0 years; 907 affected offspring with alcohol and nicotine codependence including 366 females), and (iii) a replication cohort of 449 African American cases (260 males and 189 females; 40.3 ± 7.8 years) with alcohol and nicotine codependence and 480 African American controls (170 males and 310 females; 39.6 ± 8.6 years). Additionally, a total of 38,714 subjects of European or African descent in 18 independent case-control or family-based cohorts with 10 other neuropsychiatric disorders were analyzed. These neuropsychiatric disorders included schizophrenia, autism, attention deficit hyperactivity disorder, major depression, bipolar disorder, Alzheimer's disease, amyotrophic lateral sclerosis, early onset stroke, ischemic stroke, and Parkinson's disease (Tables S1a and S1b) .
The European American discovery cohort and the African American replication cohort came from the data set of the Study of Addiction-Genetics and Environment (SAGE) (dbGaP study accession phs000092.v1.p1) , and the Australian replication cohort came from the data set of the Australian twinfamily study of alcohol use disorder (OZ-ALC) (dbGaP study accession phs000181.v1.p1) Lind et al., 2010) . All subjects with alcohol and nicotine codependence in another data set of the Collaborative Study on the Genetics of Alcoholism (COGA) (dbGaP: phs000125.v1.p1) have been included in this SAGE data set. These data sets were originally collected to study alcohol dependence alone. SAGE subjects were recruited from 8 different study sites in 7 states and the District of Columbia; the majority of subjects were recruited in Missouri . All subjects were interviewed using the Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA) (Bucholz et al., 1994) . Affected subjects met lifetime Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for both alcohol and nicotine dependence (American Psychiatric Association, 1994) . Affected subjects were excluded if they had schizophrenia or other psychotic illnesses. Controls were defined as individuals who had been exposed to alcohol and nicotine (and possibly to other drugs), but had never become dependent on these substances. Additionally, controls were also screened to exclude individuals with major Axis I disorders, including schizophrenia, mood disorders, and anxiety disorders. The Australian subjects included twins and their parents, siblings, spouses, children, and other family members. The index cases reported a history of alcohol dependence and nicotine dependence (DSM-IV). More detailed demographic information is available elsewhere Edenberg et al., 2005 Edenberg et al., , 2010 Heath et al., 2011) . The European American discovery cohort and the African American replication cohort were genotyped on the Illumina Human 1M beadchip, and the Australian cohort was genotyped on the Illumina CNV370v1 beadchip (Illumina, Inc., San Diego, CA).
Detailed demographic information, including sample sizes, ethnicity, and diagnosis of the 18 cohorts with other neuropsychiatric disorders, is shown in Table S1 or is available in dbGaP database (http://www.ncbi.nlm.nih.gov/gap). These subjects were genotyped on different Illumina or Affymetrix (Santa Clara, CA) microarray beadchip platforms. All subjects gave written informed consent to participating in protocols approved by the relevant institutional review boards (IRBs). All subjects were deidentified in this study that was approved by Yale IRB.
Imputation
After we identified a significant risk genomic region in the European American discovery cohort, we imputed that entire region (1.5 Mb at Chr5: 61,708,573 to 63,257,546 from the transcript start site [TSS] of IPO11 to the TSS of HTR1A) in all samples of 21 cohorts using the same strategy as previously (Zuo et al., in press ). Rare variants with minor allele frequencies < 0.05 were excluded.
Data Analysis
Before the association analysis, we strictly cleaned the phenotype and genotype data of all data sets (see Data S1). We tested gene-disease associations in the European American discovery cohort first, to identify the significant risk genomic regions at genome-wide significance level, and then, we imputed and carefully examined this region across 21 cohorts.
1. Genome-wide association tests in the European American discovery cohort: The allele frequencies of all cleaned markers across the genome were compared between cases and controls using genome-wide logistic regression analysis implemented in the program PLINK (Purcell et al., 2007) . Diagnosis served as the dependent variable, alleles served as the independent variables, and sex, age, the first 10 principal components, and the most significant marker (i.e., rs7445832) served as the covariates. The principal component scores of our samples were derived from all autosomal single nucleotide polymorphisms (SNPs) across the genome using principal component analysis implemented in the software package EIGENSTRAT (Price et al., 2006) . Each individual received scores on each principal component. These principal components reflected the population structure of our samples. The first principal component (PC1) separated the self-identified European American and African American subjects very well, which was highly consistent with a previous report . The second principal component (PC2) separated the self-identified Hispanic subjects from the non-Hispanic subjects. Other principal components also accounted for very small fractions of the total variance. The first 10 principal component scores accounted for >95% of variance. These PCs serving as covariates in the regression model can control for the population stratification and admixture effects on association analysis. The p-values derived from these association analyses are illustrated in Fig. 1 . Furthermore, similar association analysis was performed on the imputed data (see below). The top-ranked (p < 10
À5
) risk markers are listed in Table 1 . To mitigate false-positive rates, genome-wide associations in the discovery cohort were corrected for multiple testing by Bonferroni correction (a = 5 9 10 À8 ).
Association tests for the imputed genotype data in all samples in
21 cohorts: To analyze the associations between neuropsychiatric diseases and all imputed markers in the case-control samples, we used the logistic regression analysis described above. For the family samples, we tested associations using the program FBAT (Horvath et al., 2001 ). Association results were corrected for multiple comparisons by the effective number of SNPs within the IPO11-HTR1A region and the number of cohorts examined (i.e., n = 21). The effective marker numbers were calculated using the program SNPSpD (Li and Ji, 2005) . In the present study, the effective genetic marker number was 669 in the IPO11-HTR1A region; thus, the region-and cohort-wide corrected a was set at 3.6 9 10
À6
. The associations that were replicable between the discovery and replication cohorts are shown in Tables 2 and 3 . Meta-analysis was performed on these replicable associations, to derive the combined p-values using the program METAL (http://www.sph.umich.edu/csg/abecasis/metal/index. html). 3. Cis-acting genetic regulation of expression analysis in the lymphoblastoid cell lines: To examine relationships between all available SNPs in the IPO11-HTR1A region and mRNA expression levels of local genes (i.e., HTR1A and IPO11) in the lymphoblastoid cell lines, we performed cis-acting expression quantitative locus (cis-eQTL) analysis. Expression array data of 14,925 transcripts (14,072 genes) in 90 unrelated HapMap CEU individuals were assessed (Stranger et al., 2005) . Differences in the distribution of mRNA expression levels between SNP genotypes were compared using a Wilcoxon-type trend test. The risk SNPs that were associated with disease in the discovery cohort and had p < 0.05 in this cis-eQTL analysis are shown in the Table S2 . 4. Cis-eQTL analysis on all available SNPs in the IPO11-HTR1A region in the brain tissue samples and the peripheral blood mononuclear cell (PBMC) samples: To examine whether the SNPs in the risk region influence the local gene expression changes, we also tested the associations between the genotypes and the expression levels of exons and transcripts of local genes (i.e., HTR1A and IPO11) in 2 additional European samples (Table S2) . Expression array data in 93 autopsy-collected frontal cortical brain tissue samples with no defined neuropsychiatric condition and 80 PBMC samples collected from living healthy donors obtained from a study (Heinzen et al., 2008) at Duke University were evaluated. Each of these associations was analyzed using a linear regression model by correcting for age, sex, source of tissues, and principal component scores of ancestry. The expression array data have been confirmed by quantitative real-time polymerase chain reaction previously (Heinzen et al., 2008) .
RESULTS
We scanned the genome in the European American discovery cohort and identified a significant risk region between HTR1A and IPO11 on chromosome 5q at genome-wide significance level (Figs 1-3) , with the most significant SNP rs7445832 (p = 6.2 9 10 À9 ). We examined the 10 Mb range surrounding this SNP, which covered the entire IPO11-HTR1A region (1.5 Mb), in the discovery cohort, and found a total of 13 SNPs that had association signals for alcohol and nicotine codependence with p < 10 À4 (i.e., 6.2 9 10 À9 p 9.1 9 10
À5
). These SNPs were concentrated within a narrow region (0.5 Mb) surrounding the most significant SNP between IPO11 and HTR1A ( Fig. 2A) .
We further examined the entire IPO11-HTR1A region (1.5 Mb) in multiple populations and detected many association and functional signals (Tables 1-3 and Table S2 ). In the European American discovery cohort, among 2,726 SNPs including 261 originally genotyped SNPs and 2,465 imputed SNPs, 381 SNPs were nominally associated with alcohol and nicotine codependence (p < 0.05) (Table 4) ; 57 SNPs were significantly associated with alcohol and nicotine codependence after region-and cohort-wide correction (a = 3.6 9 10 À6 ). As mentioned, 1 of the SNPs showed evidence for genome-wide significance (rs7445832; p = 6.2 9 10 À9 ). All risk alleles of these markers were minor alleles (f < 0.5). If conditional on the most significant SNP (i.e., rs7445832), all of the associations with other SNPs became less significant (all p > 10 À4 ; Fig. 2C ). In the Australian replication cohort, 100 SNPs were nominally associated with alcohol and nicotine codependence (0.001 p 0.049; data not shown). Thirty-four associations in the discovery cohort (6.2 9 10 À9 p 0.049) were replicated in the Australian replication cohort (0.001 p 0.049) ( Table 2 and Fig. 2D ), with the same directions of gene effects in both cohorts. Meta-analysis showed that all of these 34 replicable SNPs were associated with disease (9.6 9 10 À10 p 0.021; Table 2 ), including 4 genomewide significant SNPs, that is, rs7445832 (p = 9.6 9 10 À10 ), rs13361996 (p = 8.2 9 10 À9 ), rs62380518 (p = 2.3 9 10 À8 ), and rs7714850 (p = 3.4 9 10
À8
). In the African American replication cohort, 77 SNPs were nominally associated with alcohol and nicotine codependence (0.002 p 0.049; data not shown). Eleven risk SNPs in the discovery cohort (8.1 9 10 À6 p 0.042) were also risk SNPs in the African American replication cohort (0.032 p 0.049) (Table 3) . However, all of these 11 SNPs but 1 had opposite directions of gene effects between the discovery cohort and the African American cohort. Meta-analysis showed that only this exceptional 1 SNP was associated with disease (rs10042968: OR = 1.41, p = 8.1 9 10 À6 in European Americans; OR = 1.54, p = 0.041 in African Americans; OR = 1.42, p = 8.0 9 10 À7 in meta-analysis; Table 3 ). Among these SNPs, rs690957 was a risk SNP across 3 cohorts (p = 0.008, 0.004, and 0.047 in European Americans, European Australians and African Americans, respectively). Rs690957 was also the most significant one in European Australians (Table 4) . In other 18 independent cohorts, 9-261 SNPs were nominally associated with diseases, but none of them survived region-and cohort-wide correction for multiple comparisons (Table 4) .
Cis-eQTL analysis showed that, among the risk SNPs for alcohol and nicotine codependence, 30 SNPs had nominal cis-acting regulatory effects on expression of HTR1A or IPO11 mRNA in the brain, PBMC, or lymphoblastoid cell lines (2.3 9 10 À13 p 0.05); among all of the 65 SNPs within this region that were genotyped for eQTL analysis, 43 (66.2%) were risk markers for alcohol and nicotine codependence (6.2 9 10 À9 p 0.048) (Table S2) . Cis-acting regulatory effects on IPO11 expression were much stronger than those on HTR1A expression. All of the risk alleles for alcohol and nicotine codependence increased the expression of HTR1A. However, some of the risk alleles increased the expression of IPO11, but the others decreased it.
Additionally, a total of 2,058 SNPs in ARHGAP10, MARK1, DDX6, KIAA1409, CTBP2, GRM3, TBC1D2B, BACH2, and CNTNA that were significant risk genes for alcohol dependence, alcohol and nicotine codependence, or nicotine dependence identified by Lind and colleagues (2010) were also tested in our samples. We listed all p-values <0.01 in the Table S3 . We found that none of these markers were 
All markers are in Hardy-Weinberg Equilibrium (HWE), common variants, and ordered by chromosome position; all risk alleles are minor alleles. The markers underlined are nonimputed markers. The bold are the genome-wide significant markers with p < 5 9 10 À8 in meta-analysis (see Table 2 ). SNP, single nucleotide polymorphism.
significantly associated with alcohol and nicotine codependence in our samples after Bonferroni correction.
DISCUSSION
In the European American population, we identified a genome-wide significant risk marker at the IPO11-HTR1A region specific for alcohol and nicotine codependence. The region surrounding this marker was enriched with many association signals and functional signals. We speculated that this region might harbor a causal variant for alcohol and nicotine codependence.
Several pieces of evidence supported our conclusion. First, within 10 Mb range surrounding this genome-wide 
À4
The bold are the genome-wide significant markers with p < 5 910 À8 in meta-analysis. SNP, single nucleotide polymorphism. significant risk SNP, all association signals for alcohol and nicotine codependence with p < 10 À4 were concentrated within a narrow region surrounding this SNP. This region was completely located between HTR1A and IPO11. It is, thus, highly likely that the putative causal variant for alcohol and nicotine codependence was located within this region. Second, many risk SNPs in this region had significant cis-acting regulatory effects on mRNA expression both in the PBMC and in the brain, increasing the possibility that the IPO11-HTR1A region plays a direct functional role in the disorder. Third, many associations discovered in European Americans were replicated in European Australians, and meta-analysis showed that 4 SNPs reached the genome-wide significance level. Some associations in European Americans were also replicated in African Americans. Finally, this region was specific for alcohol and nicotine codependence, not for any other nonalcoholism neuropsychiatric disorder examined. This region has been suggestively associated with alcohol dependence (75.6% nicotine dependence) in the same data set before (p = 2.3 9 10 À6 by Bierut et al., 2010; p = 2.8 9 10
À7 by Zuo et al., 2011) , but not genomewide significant (a = 5 9 10 À8 ). The association was genome-wide significant only in the subgroup with alcohol and nicotine codependence (p = 6.2 9 10 À9 ), which might suggest that this region is associated with a more severe subtype of alcohol dependence.
It is worth noting that the "causal" variants may not be identical to the "risk" markers, which is actually a common limitation of most association studies. There were other reasons for this inconsistency between the "causal" variants ; squares represent peak single nucleotide polymorphisms (SNPs). (A) Regional association plot in European American discovery cohort for a 10 Mb region around the peak association SNP (rs7445832); (B) regional association plot in European American discovery cohort for a 1 Mb region around the peak association SNP (rs7445832) [without conditioning on rs7445832]; (C) regional association plot in European American discovery cohort for a 1 Mb region around the peak association SNP (rs7445832) [conditional on rs7445832]; (D) regional association plot in Australian replication cohort for a 1 Mb region around the peak association SNP (rs7445832)]. and the "risk" markers implicated in the current study. First, none of the risk SNPs presented here were nonsynonymous. Rather, they appeared to have implications for risk and function by virtue of their being in linkage disequilibrium (LD) with a putative causal variant and/or due to their location in the regulatory region that may in turn regulated transcription of the causal variant. Second, the SNPs employed by GWAS are common, but not rare, variants. Numerous studies have shown that many gene-disease associations are not due to a single common variant, but rather due to a constellation of more rare, regionally concentrated, disease-causing variants. Thus, the signals of association credited to our common SNPs might be synthetic associations resulting from the contributions of multiple rare SNPs in the IPO11-HTR1A region, which needs to be identified by sequencing. Third, the associations in the European American discovery cohort, the associations in the replication cohorts, and the functional signals in the eQTL analysis did not perfectly match, which was probably because these risk markers were not the causal variants per se, but rather in LD with a common putative causal variant. Fourth, current evidence, including the effect sizes and the significance strength of associations, was not sufficient to fine-map the putative causal variant to any 1 of the 4 genome-wide significant risk markers, although the most significant one (i.e., rs7445832) was most likely. Sequencing is warranted to detect the actual causal variant. Finally, after conditioning on rs7445832, all association signals for other markers were significantly reduced, which might suggest that there exists only 1 putative causal locus in this region.
Our study is the first to detect the association between HTR1A and alcohol and nicotine codependence at a genome-wide significance level. HTR1A is located in 5q11.2-q13. It encodes the 5-HT1A receptor that binds the endogenous neurotransmitter serotonin (5-hydroxytryptamine, 5-HT). This receptor is a G-protein-coupled receptor that is coupled to Gi/Go and mediates inhibitory neurotransmission. In the central nervous system, 5-HT1A receptors exist in the cerebral cortex, hippocampus, septum, amygdala, and raphe nucleus in high densities. The activation of 5-HT1A receptor has been shown to increase dopamine release in the medial prefrontal cortex, striatum, and hippocampus, to impair cognition, learning, and memory by inhibiting the release of glutamate and acetylcholine in various areas of the brain, or to increase impulsivity and inhibition of addictive behaviors. This activation is therefore likely to be related to the development of alcohol dependence or nicotine dependence. This is consistent with our findings that the risk alleles of the variants in the IPO11-HTR1A region for alcohol and nicotine codependence increased the expression of HTR1A. Additionally, a well-known and functional promoter SNP of HTR1A, C-1016G (rs6295), displays differential binding to repressors and affects transcription (Lemonde et al., 2003; Strobel et al., 2003) . Its minor allele G has been reported to increase risk for alcohol dependence (Lee et al., 2009) or increase the relapse rate of alcohol dependence (Wojnar et al., 2006) , which is consistent with our conclusion that minor alleles in this region are risk alleles.
IPO11 is a flanking gene of HTR1A. It encodes the importin 11 that is a member of the karyopherin/importin-beta Only the most significant risk markers are listed. Data set no. refers to Table S1a . "Sig. Region," a 0.5 Mb significant risk region for alcohol and nicotine codependence (see Fig. 2A ).
family of transport receptors. This receptor mediates nucleocytoplasmic transport of protein and RNA cargoes (Plafker and Macara, 2000) . It has been reported that, in mice, IPO11 expression was significantly regulated by ethanol in the prefrontal cortex (Kerns et al., 2005) and in the whole embryos (Zhou et al., 2011) . In the present study, we found many alcohol and nicotine codependence-associated markers had significant cis-acting regulatory effects on IPO11 mRNA expression both in the brain and in the PBMC. Thus, IPO11 might play important roles in alcohol and nicotine codependence too.
Among CHRNA6-CHRNB3 and CHRNA5-CHRNA3-CHRNB4 regions that have been widely associated with both alcohol and nicotine dependence before Edenberg et al., 2004; Liu et al., 2010; Ray et al., 2009; Saccone et al., 2007; Thorgeirsson et al., 2010) , we only found that CHRNA6^rs6474421 was modestly associated with alcohol and nicotine codependence in the European American discovery cohort (p = 0.005). Furthermore, this modest association was not replicated in the Australian and African American replication cohorts, nor did the marker make the top-ranked gene list in the present study, consistent with previous results using the same SAGE data set Wang et al., 2011) . Additionally, the risk genes identified by Lind and colleagues (2010) were not significantly associated with alcohol and nicotine codependence in our samples after Bonferroni correction. Critical difference between the study of Lind and colleagues (2010) and ours might result from the sample heterogeneity. Finally, in the present study, only the region between the TSS of IPO11 and the TSS of HTR1A was studied. The 5′ regulatory regions, which boundaries are hard to defined, of both genes were excluded. Some information in these 5′ regulatory regions might be lost. 
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